Sorafenib Doubles PFS at 2 Years in Patients With Desmoid Tumors for 'New Standard of Care'

Press/Media

Period	22 Dec 2018

Media coverage

Title	Sorafenib Doubles PFS at 2 Years in Patients With Desmoid Tumors for 'New Standard of Care'
Media name/outlet	MedPage Today
Country/Territory	United States
Date	22/12/18
URL	https://www.medpagetoday.com/hematologyoncology/othercancers/77101
Persons	Gary Schwartz